Mainstage at the GA Life Sciences Summit

Having recently renewed our commitment to advocating for, educating and connecting our member enterprises and stakeholders, the 2023 Georgia Life Sciences Summit by Georgia Bio brought more than 300 members of the ecosystem together in Sandy Springs on November 1st.

We reconnected with friends and colleagues, made new connections, learned from academic, industry and elected leaders, shared news and awarded both the [early stage] Company Showcase Winners and the Anthony Shucker Scientific Poster Winners. 

Our CEO Maria Thacker Goethe reinforced a statement made during the October virtual town hall , as a 501c6, Georgia Bio can be more politically active and allows for future creation of a political action committee. The organization is the sole Georgia representative to the life science sector and an official partner to the national Bioscience Industry Organization and AdvaMed, which means practical discounts for purchasing programs, but also provision of a connection to federal government affairs representation to those sectors. 

Session by session, we offer the following highlights from our colleague Paul Snyder.

Introducing the new CEO at the Georgia Research Alliance

Mainstage at the GA Life Sciences Summit

In literally his first day on the job, Timothy Denning, President and CEO of the Georgia Research Alliance introduced himself and highlighted its impact in the life science innovation ecosystem with the following statistics: 87% of GRA funded startups are still in business four years hence – the national average is just 44%. Further every $1 invested by GRA through its commercialization funding programs has returned $19 in follow on investment in or by those portfolio companies.

Mr. Denning specifically pointed to GRA life science portfolio companies Micron Biomedical (microneedle drug delivery) and EarliTec (early diagnosis of autism) as standouts for what’s possible when marshaling the right resources in promising technologies brought forth by the state’s universities, its faculty, investigators and researchers. 

Scientific Poster Award Winners

We also congratulate the Anthony Shuker Scientific Poster Award Winners and thank our judges Stacy Shuker Reece, Rick Hillstead and Jamie Graham. Thank you to all the applicants. View a list of the finalists and all the submission here :

  • Grace Nguyen , University of Georgia: Multifunctional Nitric Oxide-Releasing and Slippery Surface for Enhanced Antibacterial and Anti-fouling Therapeutic Efficacy
  • Dedeepya Pasupuleti , College of Pharmacy, Mercer University; Marissa D’Souza, University of Michigan: Advancing Drug Delivery to the Brain: Developing a Novel Nanoparticulate System Using Microfluidics to Enhance Central Drug Availability
  • Jannatul Ruhan Raha , Georgia State University: mIntranasal Vaccination with Multi-subtype Neuraminidase and M2 Ectodomain Virus-like Particle Improves Protection Against Influenza Viruses
  • Rick Hillstead Medical Device Award : Dominique Monroe , Medical College of Georgia – Augusta University: Modulated dNTP Pools and Their Influence on DNA Repair Mechanisms and Apoptosis in Therapy Resistant Cancers

Company Showcase Winners

We congratulate the Company Showcase Winners. And thank you to all presenters and judges in the Company Showcase and Rapid Fire Research Showcase.

  • 2023 Company Showcase Winner: Nutrivert , Horace Nalle
  • 2023 Company Showcase Runner-Up: EnOPrep , Austin Tull

Summit 2023: Click a Post Below for a Comprehensive Dive to What We Heard and Learned at the 2023 Georgia Life Sciences Summit

In closing, we thank everyone who helped bring the event and the ecosystem together. This includes our production team, volunteers, showcase and poster judges and sponsors without which this is simply not possible. We encourage you to consider ways to support their interests, goals and businesses.

We hope everyone involved derived high value from our latest response to the life science industry’s need: bringing the ecosystem together to advance our advocacy, education and inspiration through an industry that means more to more lives at home and abroad than we can measure.

Stay in the loop by following Georgia Bio on LinkedIn , Instagram and Twitter/X. You can also subscribe to our weekly bioBEAT by emailing us at admin@gabio.org.

——————————————————————–

By Sheran Brown February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community
By Sheran Brown February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.
By Sheran Brown February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: